In unveiling its third pipeline company of 2023, the NY-based biotech aims to improve cell fitness of CAR-T cells for …
Continue reading “Cambrian Bio launches Telos Biotech to enable more robust cell therapies”
Amplifier Therapeutics is going after “one of the most sought-after drug targets in aging research”. Cambrian Bio, a clinical-stage biotech …
Continue reading “Cambrian Bio reveals new pipeline company with focus on AMPK activation”
Isterian Biotech will focus on developing novel drugs to stop and reverse the pathological accumulation of crosslinked proteins commonly observed …
Continue reading “Cambrian BioPharma unveils new pipeline company”
Licensed rapamycin compounds to prevent age-related physiologic decline and lengthen healthspan will be developed by new Cambrian subsidiary Tornado Therapeutics …
Cambrian Biopharma’s $100 million Series C will advance healthspan-boosting therapeutics with financing co-led by Anthos Capital and SALT Fund. Longevity …
Continue reading “Cambrian closes $100m to advance therapeutics to clinic”
Cambrian’s Dr Daisy Robinton on the basis of sex, ovarian aging and improving clinical trials and education. Dr Daisy Robinton …
Continue reading “Cambrian Biopharma – Dr Daisy Robinton Q&A”
Longevity biotech exclusive Q&A with Cambrian Biopharma’s CEO – hallmarks of aging and classifying aging as a disease. Dr James …
Longevity biotech exclusive Q&A with Cambrian Biopharma’s Chief Operating Officer. Recently we reported on Cambrian Biopharma, a New York-based biotech …
New York-based biotech raises $60 million to develop a pipeline of companies and therapeutics to treat diseases of aging under …
Continue reading “Cambrian Biopharma exits stealth with $60m and affiliate IPO”
